Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

Marcelo Cruz; Tomás Reinert; Massimo Cristofanilli

doi:10.1002/cpt.965

Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

Marcelo Cruz^*, Tomás Reinert, Massimo Cristofanilli

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.

Original language	English (US)
Pages (from-to)	1009-1019
Number of pages	11
Journal	Clinical pharmacology and therapeutics
Volume	103
Issue number	6
DOIs	https://doi.org/10.1002/cpt.965
State	Published - Jun 2018

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.965

Cite this

@article{9446955028dc4d179b64f8012c682d5c,

title = "Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer",

abstract = "Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.",

author = "Marcelo Cruz and Tom{\'a}s Reinert and Massimo Cristofanilli",

year = "2018",

month = jun,

doi = "10.1002/cpt.965",

language = "English (US)",

volume = "103",

pages = "1009--1019",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

AU - Cruz, Marcelo

AU - Reinert, Tomás

AU - Cristofanilli, Massimo

PY - 2018/6

Y1 - 2018/6

N2 - Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.

AB - Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85045754758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045754758&partnerID=8YFLogxK

U2 - 10.1002/cpt.965

DO - 10.1002/cpt.965

M3 - Review article

C2 - 29226311

AN - SCOPUS:85045754758

SN - 0009-9236

VL - 103

SP - 1009

EP - 1019

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this